Use of the respiratory fluoroquinolones for the outpatient management of community-acquired pneumonia

Current Therapeutic Research - Clinical and Experimental

Volumn 65, Issue 3, 2004, Pages 225-238

  Liu, Hans H ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Universidad de Bryn Mawr   (United States)

Author keywords

clinical efficacy; community acquired pneumonia; fluoroquinolones; safety

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CLINAFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; PROCAINE PENICILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TEMAFLOXACIN; TROVAFLOXACIN;

ANAPHYLAXIS; ANTIBACTERIAL ACTIVITY; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; LIVER TOXICITY; NAUSEA; NONHUMAN; PHOTOTOXICITY; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; RASH; REVIEW; STREPTOCOCCUS PNEUMONIAE; TASTE DISORDER; TENDON DISEASE; TORSADE DES POINTES; VOMITING;

EID: 5444274997     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(04)80047-X     Document Type: Article

References (64)

1. Bartlett JG, and Mundy LM Community-acquired pneumonia N Engl J Med 333 1995 1618 1624
2. Bartlett JG, Dowell SF, and Mandell LA for the Infectious Diseases Society of America Practice guidelines for the management of community-acquired pneumonia in adults Clin Infect Dis 31 2000 347 382
3. Mandell LA, Bartlett JG, and Dowell SF for the Infectious Diseases Society of America Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults Clin Infect Dis 37 2003 1405 1433
4. Niederman MS, Mandell LA, and Anzueto A for the American Thoracic Society Guidelines for the management of adults with community-acquired pneumonia Diagnosis, assessment of severity, antimicrobial therapy, and prevention Am J Respir Crit Care Med 163 2001 1730 1754
5. Fine MJ, Smith MA, and Carson CA Prognosis and outcomes of patients with community-acquired pneumonia A meta-analysis JAMA 275 1996 134 141
6. Marston BJ, Plouffe JF, File TM Jr for the Community-Based Pneumonia Incidence Study Group Incidence of community-acquired pneumonia requiring hospitalization Results of a population-based active surveillance study in Ohio Arch Intern Med 157 1997 1709 1718
7. Falguera M, Sacristan O, and Nogues A Nonsevere community-acquired pneumonia: Correlation between cause and severity or comorbidity Arch Intern Med 161 2001 1866 1872
8. Bochud P-Y, Moser F, and Erard P Community-acquired pneumonia A prospective outpatient study Medicine (Baltimore) 80 2001 75 87
9. Karlowsky JA, Thornsberry C, and Jones ME for the TRUST Surveillance Program Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: Results from the TRUST Surveillance Program (1998-2002) Clin Infect Dis 36 2003 963 970
10. Doern GV, Heilmann KP, and Huynh HK Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995 Antimicrob Agents Chemother 45 2001 1721 1729
11. Jones ME, Karlowsky JA, and Blosser-Middleton R Longitudinal assessment of antipneumococcal susceptibility in the United States Antimicrob Agents Chemother 46 2002 2651 2655
12. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN for the Alexander Project Group The Alexander Project 1998-2000: Susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents J Antimicrob Chemother 52 2003 229 246
13. Lynch JP 3rd, and Martinez FJ Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia Clin Infect Dis 34 Suppl 1 2002 S27 S46
14. Lonks JR What is the clinical impact of macrolide resistance? Curr Infect Dis Rep 6 2004 7 12
15. Resistance of Streptococcus pneumoniae to fluoroquinolones - United States, 1995-1999 MMWR Morb Mortal Wkly Rep 50 2001 800 804
16. File TM Jr, Segreti J, and Dunbar L A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia Antimicrob Agents Chemother 41 1997 1965 1972
17. Fogarty C, Siami G, and Kohler R Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin vs ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin/clavulanate in the treatment of serious community-acquired pneumonia in adults Clin Infect Dis 38 Suppl 1 2004 S16 S23
18. Fogarty C, Dowell M, and Ellison W Treating community-acquired pneumonia in hospitalized patients: Gatifloxacin vs ceftriaxone/clarithromycin J Respir Dis 20 Suppl 11 1999 560 569
19. Fogarty C, Grossman C, and Williams J Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia Infect Med 16 1999 748 763
20. Salkind AR, Cuddy PG, and Foxworth JW Fluoroquinolone treatment of community acquired pneumonia: A meta-analysis Ann Pharmacother 36 2002 1938 1943
21. Fogarty CM, Greenberg RN, and Dunbar L Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: Integrated Results from four open-label, multicenter, phase III clinical trials Clin Ther 23 2001 425 439
22. Fogarty CM, Sullivan JG, and Chattman MS Once a day levofloxacin in the treatment of mild to moderate and severe community-acquired pneumonia in adults Infect Dis Clin Pract 7 1998 400 407
23. Akpunonu B, Michaelis J, and Tennenberg A Multicenter, postmarketing assessment of levofloxacin in the treatment of adults with community-acquired pneumonia Clin Infect Dis 38 Suppl 1 2004 S5 S15
24. Kahn JB, Wiesinger BA, and Xiang J Macrolide-resistant Streptococcus pneumoniae in community-acquired pneumonia: Clinical and microbiological outcomes for patients treated with levofloxacin Clin Infect Dis 38 Suppl 1 2004 S24 S33
25. [published correction appears in Drugs. 2002; 62: 944] Zhanel GG, Ennis K, and Vercaigne L A critical review of the fluoroquinolones: Focus on respiratory infections Drugs 62 2002 13 59
26. File TM Jr, Schlemmer B, Garau J for the 049 Clinical Study Group Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: A randomized, double-blind comparison with trovafloxacin JAntimicrob Chemother 48 2001 67 74
27. Sullivan JG, McElroy AD, and Honsinger RW A double-blind, randomized study of safety and efficacy: Treating community-acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin J Respir Dis 20 Suppl 10 1999 549 559
28. Bertino J Jr, and Fish D The safety profile of the fluoroquinolones Clin Ther 22 2000 798 817
29. (Suppl) Fish DN Fluoroquinolone adverse effects and drug interactions Pharmacotherapy 21 2001 S253 S272
30. Mandell L, and Tillotson G Safety of fluoroquinolones: An update Can J Infect Dis 13 2002 54 61
31. Levaquin® (levofloxacin) 2003 Ortho-McNeil Pharmaceuticals, Inc
32. TM (gatifloxacin) 2002 Bristol-Myers Squibb Co Raritan, NJ
33. Avelox® (moxifloxacin hydrochloride) 2002 Bayer Corporation Princeton, NJ
34. Lipsky BA, and Baker CA Fluoroquinolone toxicity profiles: A review focusing on newer agents Clin Infect Dis 28 1999 352 364
35. Ball P, Mandell L, Niki Y, and Tillotson G Comparative tolerability of the newer fluoroquinolone antibacterials Drug Saf 21 1999 407 421
36. Khaliq Y, and Zhanel GG Fluoroquinolone-associated tendinopathy: A critical review of the literature Clin Infect Dis 36 2003 1404 1410
37. Chien SC, Chow AT, and Natarajan J Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects Antimicrob Agents Chemother 41 1997 1562 1565
38. Stahlmann R, and Lode H Fluoroquinolones in the elderly: Safety considerations Drugs Aging 20 2003 289 302
39. Blum MD, Graham DJ, and McCloskey CA Temafloxacin syndrome: Review of 95 cases Clin Infect Dis 18 1994 946 950
40. Frothingham R Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin Pharmacotherapy 21 2001 1468 1472
41. discussion Owens RC Jr, and Ambrose PG Torsades de pointes associated with fluoroquinolones Pharmacotherapy 22 2002 663 668
42. Owens RC Jr, and Ambrose PG Torsades de pointes associated with fluoroquinolones Pharmacotherapy 22 2002 668 672
43. Demolis JL, Kubitza D, Tenneze L, and Funck-Brentano C Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects Clin Pharmacol Ther 68 2000 658 666
44. Noel GJ, Natarajan J, and Chien S Effect of three fluoroquinolones on QT interval in healthy adults after single doses Clin Pharmacol Ther 73 2003 292 303
45. Baker SE, and Hangii MC Possible gatifloxacin-induced hypoglycemia Ann Pharmacother 36 2002 1722 1726
46. Menzies DJ, Dorsainvil PA, Cunha BA, and Johnson DH Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents Am J Med 113 2002 232 234
47. Thomas C, Stevenson M, and Riley TV Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: A systematic review JAntimicrob Chemother 51 2003 1339 1350
48. Donskey CJ, Chowdhry TK, and Hecker MT Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients N Engl J Med 343 2000 1925 1932
49. Gunderson BW, Ross GH, Ibrahim KH, and Rotschafer JC What do we really know about antibiotic pharmacodynamics? Pharmacotherapy 21 Suppl 11 2001 S302 S318
50. Hurst M, Lamb HM, Scott LJ, and Figgitt DP Levofloxacin: An updated review of its use in the treatment of bacterial infections Drugs 62 2002 2127 2167
51. Chien SC, Wong FA, and Fowler CL Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers Antimicrob Agents Chemother 42 1998 885 888
52. 2003 Drug Topics® Red Book® 2003 Thomson PDR West Haven, Conn
53. Witt RL, and Hamburger M The nature and treatment of pneumococcal pneumonia Med Clin North Am 47 1963 1257 1270
54. Awunor-Renner C Length of antibiotic therapy in in-patients with primary pneumonias Ann Trop Med Parasitol 73 1979 235 240
55. Claxton AJ, Cramer J, and Pierce C A systematic review of the associations between dose regimens and medication compliance Clin Ther 23 2001 1296 1310
56. Kardas P Once-daily dosage secures better compliance with antibiotic therapy of respiratory tract infections than twice-daily dosage J Appl Res 3 2003 201 206
57. Available at: www.who.int/infectious-diseasereport/2000/intro.htm. Accessed May 15, 2004 World Health Organization (WHO) Web site Overcoming antimicrobial resistance: World Health Organization Report on Infectious Diseases 2000 WHO/CDS/2000.2. 2000 2000 WHO Montvale, NJ
58. Reyes H, Guiscafre H, and Munoz O Antibiotic noncompliance and waste in upper respiratory infections and acute diarrhea J Clin Epidemiol 50 1997 1297 1304
59. Schrag SJ, Pena C, and Fernandez J Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: A randomized trial JAMA 286 2001 49 56
60. Gotfried MH, Danziger LH, and Rodvold KA Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects Chest 119 2001 1114 1122
61. Lister PD Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae Diagn Microbiol Infect Dis 44 2002 43 49
62. [published correction appears in Clin Infect Dis. 2003; 37: 1147] Dunbar LM, Wunderink RG, and Habib MP High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm Clin Infect Dis 37 2003 752 760
63. Fine MJ, Auble TE, and Yealy DM A prediction rule to identify low-risk patients with community-acquired pneumonia N Engl J Med 336 1997 243 250
64. Echols RM The approval process for intravenous ciprofloxacin Infect Med 9 Suppl D 1992 23 31